Major Depressive Disorder (MDD) is one of the most common mental disorder characterized by persistent and tenacious low mood that interferes with the person’s ability to work, eat, sleep and normal activities. MDD is also referred as clinical depression, major depression, and unipolar depression or as recurrent depression. The common symptoms associated with this disorder include insomnia, loss of interest, recurrent thoughts of death, feelings of worthlessness and reduced ability to think. Increasing number of patients suffering from MDD has grabbed the attention of MDD drugs manufacturer to invest into MDD treatment market.
Major Depressive Disorder (MDD) Treatment Market: Drivers and Restraints
Work life imbalances due to change in life style, and increase in MDD patient pool are the key drivers expected to drive the MDD treatment market over the forecasted period. Partnerships for co-development and co-marketing of MDD drugs among the drug manufactures across the globe, development of new drugs, and adequate government reimbursement policies have also fueled the growth of MDD treatment market. However, stringent regulations imposed by various governments for new drug approval, patent expiries of some blockbuster drugs, risk of complications with other medications, and related side effects of MDD drugs may hinder the growth of MDD treatment market over the forecasted period.
Request Free Report Sample@ http://www.futuremarketinsights.com/reports/sample/rep-gb-1314
Major Depressive Disorder (MDD) Treatment Market: Segmentation
The global MDD treatment market is segmented based on drug type used for the treatment of MDD.
- Selective Serotonin Reuptake Inhibitors (Ssris)
- Dopamine Norepinephrine Reuptake Inhibitor
- Serotonin Norepinephrine Reuptake Inhibitor
- Serotonin Modulators
- Norepinephrine-Serotonin Modulator
- Tricyclics and Tetracyclics
- Monoamine Oxidase Inhibitors (MAOIs)
- Irreversible, non-selective inhibitors
- Irreversible, MAO B selective inhibitor
- Selegiline transdermal
- Reversible, MAO A selective inhibitor
- Atypical antidepressants
Major Depressive Disorder (MDD) Treatment Market: Overview
At present, antidepressants are most commonly used drugs for the treatment of MDD, and has the largest market segment. Major brands of SSRI’s include Citalopram, Escitalopram, Fluoxetine, Paroxetine, and Sertraline. Bupropion, Mirtazapine, and Razodone, are atypical antidepressants frequently used for the treatment of MDD. Major brands of antipsychotics includes Resperidone, Olanzapine, Quetiapine, Ziprasidone, and Aripiprazole. Global MDD treatment market is expected to grow with a healthy CAGR owing to increase in MDD patient pool over the forecast period.
Request For TOC@ http://www.futuremarketinsights.com/toc/rep-gb-1314
Major Depressive Disorder (MDD) Treatment Market: Region-wise Outlook
Geographically, North America market is estimated to hold maximum market revenue share in global MDD treatment market owing to increase in number of patients suffering from MDD, and advancement in technology to develop new therapeutic drugs and followed by Europe and Asia-Pacific respectivily. The market in Asia-Pacific is expected to expand at a significant CAGR over the forecasted period due to increasing awareness for depression conditions and complications associated with it. MDD treatment market is expected to register healthier CAGR in emerging markets such as India, China, and Brazil compared to other developed regions in the world.
Major Depressive Disorder (MDD) Treatment Market: Key Players
Key companies operational in MDD treatment market are Eli Lilly and Company, Johnson & Johnson, Pfizer, Inc., AstraZeneca plc, Merck & Co., GlaxoSmithKline plc, Sanofi S.A., Shire plc, Novartis AG, Janssen Pharmaceutical, Inc., and others.